Welcome to the website of Lipopharma, a pioneering clinical-stage biopharmaceutical company that focuses on the discovery, design and clinical development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT).
Lipopharma arose in 2006 as an academic spin-off of the cellular and molecular biomedicine research group at the University of the Balearic Islands (UIB) in Mallorca, Spain.
Palma de Mallorca, April 19th, 2016. – Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of bio-active lipids based on the groundbreaking MLT platform, announced that today the main results of the dose-escalation (DE) part of MIN-001-1203 clinical study with Minerval in patients with advanced solid tumours, including malignant glioma, were presented at the 2016 AACR meeting in New Orleans, LA, by Dr. J. Lopez, Principal Investigator at Royal Marsden Hospital, London, in this study.
Palma de Mallorca, November 23rd, 2015.– Lipopharma announced today that in the Dose Escalation TC held this morning with all the Clinical Investigators and the Medical Monitor of the MIN-001-1203 study with Minerval, it was agreed that the Maximum Tolerated Dose (MTD) in this study will be set as 12g per day (4g TDS, three times daily). As from today two additional safety expansion cohorts (one with 10 glioma patients and another with 10 patients with solid biopsiable tumours) will start recruiting participants at a dose of 12g/day (4g TDS) in order to evaluate the effect of Minerval in different biomarkers and to further explore preliminary efficacy in glioma patients.